Compare ARBEW & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBEW | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 171.9M |
| IPO Year | 2021 | 2020 |
| Metric | ARBEW | BDTX |
|---|---|---|
| Price | $0.02 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 64.3K | ★ 487.0K |
| Earning Date | 03-05-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $1.60 |
| 52 Week High | $0.50 | $4.94 |
| Indicator | ARBEW | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 41.85 |
| Support Level | $0.02 | $1.61 |
| Resistance Level | $0.04 | $2.28 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 26.92 | 3.75 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.